Editorial: expanding a narrow perspective on narrow calibre oesophagus in eosinophilic oesophagitis

Editorial: prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis

“…The autoimmune liver disease, primary sclerosing cholangitis (PSC) remains an enigma; the aetiopathogenesis remains unknown, and medical treatment options are limited. 1 However, whilst earlier studies from tertiary centres suggested a median survival of 8-10 years, recent studies have shown a median survival of 21 years. 2 With the advent of new therapies in development for PSC, the need for accurate surrogate endpoints in place of survival free of liver transplantation or death has become increasingly important.…”

“…This study answers this important question and furthermore identifies factors which predict response. 1 All patients in the study (n = 73) had previous exposure to IFX, early ADA levels available, and ≥1 year follow-up after commencing ADA therapy. Short-term response was defined as an improvement in the partial Mayo score at week 12, with long-term response defined as continued treatment with ADA, without the need for corticosteroids by week 52.…”

Editorial: expanding a narrow perspective on narrow calibre oesophagus in eosinophilic oesophagitis – authors' reply

“…We would like to thank Drs Molina‐Infante and Hirano for their supportive and thorough editorial comments on our paper . With regard to the important issues raised, we would like to make two points.…”